AR and prostate carcinoma: Several studies highlighted the key role played by the androgen-receptor (AR) axis in prostate cancer pathogenesis and subsequent progression, explaining the rationale of the use of androgen-deprivation therapy (ADT) as upfront treatment in metastatic prostate malignancy [5,6].